Navigation Links
Sofie Biosciences Is Awarded a US Patent on a Family of Novel PET Probes for Use in Oncology and Immunology
Date:1/24/2012

CULVER CITY, Calif., Jan. 24, 2012 /PRNewswire/ -- Sofie Biosciences, Inc., offering a comprehensive range of products from pre-clinical PET imaging systems to new PET molecular imaging probes to better understand human disease, has been told that a U.S. Patent (8,101,740) will be granted by the United States Patent Office on technology that has been exclusively licensed to Sofie. The patent covers a family of novel PET probes, known as [18F]FAC.

Positron Emission Tomography (PET) is a molecular imaging technology that utilizes minute amounts of labeled molecules ("probes") to target and measure biological and pharmacological processes. Basic scientists can use the same probes to examine cells and mice, as physicians do in patients to visualize and characterize the biology of disease, monitor its progression, and evaluate therapeutic efficacy.

Basic and clinical scientists at UCLA invented this novel PET probe, [18F]FAC, which was created by a slight modification of the drug molecule, gemcitabine, one of the most common drugs for cancer.  Cancer cells lack the normal checks and balances to limit cell growth.  [18F]FAC provides an in vivo imaging assay of cell growth known as the DNA salvage pathway.  Tumors use the salvage pathway to provide high rates of DNA replication for their uncontrolled growth of cells containing malignant instructions.

[18F]FAC measures the enzyme, dCK, which controls the rate of DNA production through the salvage pathway. Cancer drugs like gemcitabine use dCK to convert the drug into a pharmacologically active product that blocks the high rates of DNA replication for growth of malignant cells, and induces DNA damage in cancer cells. One of Sofie's objectives with [18F]FAC is to use PET imaging to allow physicians the means to search throughout the body for tumors that will respond to drugs that target dCK (like gemcitabine and other drugs), thus enabling more patient-specific treatment selection.

Cells of the immune system also use the salvage pathway to replicate activated immune cells in response to pathogens in the body and show differential uptake of [18F]FAC when they are activated. Such a non-invasive imaging test could help physicians more effectively examine and measure the activity of immune system throughout the body.

"[18F]FAC is a remarkable imaging probe. It specifically targets a single enzyme, dCK, and when that target is removed, the signal is absent. [18F]FAC displays rapid in vivo transport into cells, dCK dependent accumulation, sufficient in vivo stability, and because of trace amounts of [18F]FAC used, no evidence has been found for neither pharmacologic effects nor the toxicity in humans. Making [18F]FAC available for broad use in both academic and commercial research communities is the next step in the milestones of the imaging probe segment of Sofie's business," said Patrick Phelps, Sofie's President and CEO. The instrumentation arm of Sofie provides technologies for [18F]FAC production and pre-clinical PET imaging to facilitate and simplify the use of [18F]FAC and other PET imaging probes in academic and commercial research.

Sofie has obtained an exclusive license from The Regents of the University of California. Three investigational new drug (IND) applications have been approved for [18F]FAC and two analogs, and clinical trials have been initiated. 

About Sofie Biosciences
Sofie is combining new PET imaging agents with innovative imaging systems to provide researchers and physicians with tools to better investigate the biology of disease. By empowering a wide array of people with valuable, translational imaging tools, Sofie is making PET scans more accessible and increasing the diversity of its applications.

For additional information, contact Dr. Jennifer Cho at 424.223.6948 or jennifer.cho@sofiebio.com.


'/>"/>
SOURCE Sofie Biosciences
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sofie Biosciences is Awarded a DOE Phase I SBIR to Commercialize Microscale Radiochemistry Platform
2. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2008
3. Carna Biosciences Signs Reagent Supply Agreement with Caliper Life Sciences
4. Pressure BioSciences, Inc. to Discuss Second Quarter 2008 Financial Results and Provide Business Update
5. Milestone Biosciences, LLC Further Strengthens Executive Management Team
6. Pressure BioSciences, Inc. Reports Second Quarter 2008 Financial Results and Provides Business Update
7. Access Pharmaceuticals Licenses MuGard to Milestone Biosciences, LLC for North America
8. Pressure BioSciences, Inc. Releases Novel, PCT-dependent Sample Preparation Kit for Systems Biology Studies
9. Neurocrine Biosciences to Present at Thomas Weisel Healthcare Conference and the NewsMakers in the Biotech Industry Conference
10. Start-Up and Emerging Biotech Companies Will Tell Their Stories at Biosciences Showcase Planned for MichBio Expo
11. Ardea Biosciences to Present Data on Lead MEK inhibitor, RDEA119, at EORTC-NCI-AACR Symposium
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... DIEGO , Dec. 6, 2016  Creative Medical ... Kesari , MD, PhD, FANA, FAAN to the Company,s ... neurology and clinical trials to assist the Company,s clinical ... stroke. The AmnioStem product is a universal donor stem cell ... activity in animal models of stroke 1 .  ...
(Date:12/6/2016)... 6, 2016  The Texas Medical Center ... (HISA) today announced the establishment of a new ... Australia and the Texas Medical ... HISA and the Texas Medical Center, with ... create a global health innovation ecosystem where emerging technologies ...
(Date:12/5/2016)... Axovant Sciences Ltd. (NYSE: AXON ... treatment of dementia, today announced that data on the ... disease will be presented at the 2016 Clinical Trials ... 2016 in San Diego . Intepirdine ... and complex measures of activities of daily living (ADLs) ...
(Date:12/5/2016)... ... December 05, 2016 , ... The Real Dirt with ... cannabis technology and application experts, Chip Baker. Chip Baker formerly co-founded Royal Gold ... past 30 years, Chip Baker other industry veterans have made the evolution of ...
Breaking Biology Technology:
(Date:12/7/2016)... , Dec. 7, 2016   Avanade is ... Formula One teams in history, exploit biometric data in ... performance and maintain the competitive edge against their rivals ... Avanade has worked with Williams during ... of biometric data (heart rate, breathing rate, temperature and ...
(Date:12/6/2016)... N.C. , Dec. 6, 2016 Valencell ... announced today it has seen a third consecutive year ... biometric sensor technology in 2016 with a 360 percent ... last year. This increase was driven by sales of ... as robust interest in its technology for hearables for ...
(Date:12/2/2016)... India , December 1, 2016 ... Authentication type (Fingerprint, Voice), Future Technology (Iris Recognition ... and Region - Global Forecast to 2021", published ... USD 442.7 Million in 2016, and is projected ... at a CAGR of 14.06%.      ...
Breaking Biology News(10 mins):